Reproducibility and absolute quantification of muscle glycogen in patients with glycogen storage disease by 13C NMR spectroscopy at 7 tesla

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Heinicke, Katja ^a,b   Dimitrov, Ivan E ^c,d   Romain, Nadine ^a   Cheshkov, Sergey ^c   Ren, Jimin ^c   Malloy, Craig R ^c   Haller, Ronald G ^a,b,e  

^a PRESBYTERIAN HOSPITAL OF DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d PHILIPS HEALTHCARE   (United States)

^e VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTOKINASE; GLYCOGEN;

ADULT; ARTICLE; BIOCHEMISTRY; CARBON NUCLEAR MAGNETIC RESONANCE; CASE REPORT; CONTROLLED STUDY; ENZYME DEFICIENCY; FEASIBILITY STUDY; FEMALE; GASTROCNEMIUS MUSCLE; GLYCOGEN MUSCLE LEVEL; GLYCOGEN STORAGE DISEASE TYPE 5; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MUSCLE BIOPSY; NEEDLE BIOPSY; PHANTOM; REPRODUCIBILITY; SIGNAL NOISE RATIO; ADOLESCENT; GLYCOGEN STORAGE DISEASE; METABOLISM; MIDDLE AGED; PROCEDURES; SKELETAL MUSCLE; YOUNG ADULT;

ADOLESCENT; ADULT; CARBON-13 MAGNETIC RESONANCE SPECTROSCOPY; FEMALE; GLYCOGEN; GLYCOGEN STORAGE DISEASE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84907727620     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108706     Document Type: Article

References (25)

1. DiMauro S (2007) Muscle glycogenoses: an overview. Acta Myol 26: 35-41.
2. Haller RG, Vissing J (2004) Functional evaluation of metabolic myopathies. In: Engel AG, Franzini-Armstrong C, editors. Myology. 3nd ed. New York: McGraw-Hill. pp. 665-679.
3. Haller RG, Vissing J (2002) Spontaneous "second wind" and glucose-induced second "second wind" in McArdle disease: oxidative mechanisms. Arch Neurol 59: 1395-1402.
4. Haller RG, Vissing J (2004) No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology 62: 82-86.
5. Lucia A, Nogales-Gadea G, Perez M, Martin MA, Andreu AL, et al. (2008) McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol 4: 568-577.
6. Sharp LJ, Haller RG (2014) Metabolic and Mitochondrial Myopathies. Neurol Clin 32: 777-799.
7. Boesch C (2007) Musculoskeletal spectroscopy. J Magn Reson Imaging 25: 321-338.
8. Stephenson MC, Gunner F, Napolitano A, Greenhaff PL, Macdonald IA, et al. (2011) Applications of multi-nuclear magnetic resonance spectroscopy at 7T. World J Radiol 3: 105-113.
9. Kreis R (1997) Quantitative localized 1H MR spectroscopy for clinical use. Prog Nucl Magn Reson Spectrosc 31: 155-195.
10. Zang LH, Laughlin MR, Rothman DL, Shulman RG (1990) 13C NMR relaxation times of hepatic glycogen in vitro and in vivo. Biochemistry 29: 6815-6820.
11. DiMauro S, Hartwig GB, Hays A, Eastwood AB, Franco R, et al. (1979) Debrancher deficiency: neuromuscular disorder in 5 adults. Ann Neurol 5: 422-436.
12. Mendez J, Keys A (1960) Density and composition of mammalian muscle. Metabolism 9: 184-188.
13. Jehenson P, Duboc D, Bloch G, Fardeau M, Syrota A (1991) Diagnosis of muscular glycogenosis by in vivo natural abundance 13C NMR spectroscopy. Neuromuscul Disord 1: 99-101.
14. Jehenson P, Duboc D, Labrune P, Fardeau M, Odievre M, et al. (1995) Diagnostic value of the evaluation of glycogen content in muscle diseases by carbon 13 nuclear magnetic resonance. J Chim Phys 92: 1797-1800.
15. Wary C, Laforet P, Eymard B, Fardeau M, Leroy-Willig A, et al. (2003) Evaluation of muscle glycogen content by 13C NMR spectroscopy in adult-onset acid maltase deficiency. Neuromuscul Disord 13: 545-553.
16. Beckmann N, Seelig J, Wick H (1990) Analysis of glycogen storage disease by in vivo 13C NMR: comparison of normal volunteers with a patient. Magn Reson Med 16: 150-160.
17. Murphy E, Hellerstein M (2000) Is in vivo nuclear magnetic resonance spectroscopy currently a quantitative method for whole-body carbohydrate metabolism? Nutr Rev 58: 304-314.
18. Roach PJ, Depaoli-Roach AA, Hurley TD, Tagliabracci VS (2012) Glycogen and its metabolism: some new developments and old themes. Biochem J 441: 763-787.
19. Avison MJ, Rothman DL, Nadel E, Shulman RG (1988) Detection of human muscle glycogen by natural abundance 13C NMR. Proc Natl Acad Sci USA 85: 1634-1636.
20. Taylor R, Price TB, Rothman DL, Shulman RG, Shulman GI (1992) Validation of 13C NMR measurement of human skeletal muscle glycogen by direct biochemical assay of needle biopsy samples. Magn Reson Med 27: 13-20.
21. Haller RG, Wyrick P, Taivassalo T, Vissing J (2006) Aerobic conditioning: an effective therapy in McArdle's disease. Ann Neurol 59: 922-928.
22. Mate-Munoz JL, Moran M, Perez M, Chamorro-Vina C, Gomez-Gallego F, et al. (2007) Favorable responses to acute and chronic exercise in McArdle patients. Clin J Sport Med 17: 297-303.
23. Bergstrom J, Hultman E (1966) Muscle glycogen synthesis after exercise: an enhancing factor localized to the muscle cells in man. Nature 210: 309-310.
24. Andersen ST, Haller RG, Vissing J (2008) Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. Arch Neurol 65: 786-789.
25. Vissing J, Lewis SF, Galbo H, Haller RG (1992) Effect of deficient muscular glycogenolysis on extramuscular fuel production in exercise. J Appl Physiol 72: 1773-1779.